Blood
Articles in this Issue
A randomized, double-blind, placebo-controlled trial of a novel BTK inhibitor (rilzabrutinib) in patients with sickle cell disease (SCD) aged 10–65 years: LIBRA Study
Abstract Sickle Cell Disease (SCD) is a multisystem disorder caused by mutations in the HBB gene, leading to hemoglobin S polymerization fol...
U2AF1S34F mutant HSPCs have a fitness advantage in aged and inflamed bone marrow
Abstract Introduction. Clonal Hematopoiesis of Indeterminant Potential (CHIP) associated splicing factor mutations, such as U2AF1S34F, are s...
Decoding the gene regulatory response to iron through multiomics
Abstract Background: Normal cellular functions rely on iron, making dietary intake crucial for maintaining iron levels. Iron deficiency (ID)...
The impact of day of admission on morbidity and mortality outcomes on patients with febrile neutropenia in the United States: A nationwide analysis
Abstract Purpose There is limited data regarding the impact of the admission day on patients with febrile neutropenia. Past literature has s...
Impact of pre-transplant cytoreductive therapy on post-transplant outcomes in patients with myelodysplastic syndromes with excess of blasts: A retrospective analysis
Abstract Background: Myelodysplastic syndromes (MDS) are malignant hematologic disorders characterized by ineffective hematopoiesis and an i...
Next-generation sequencing (NGS) of DNA isolated from nail specimens and run in parallel with tumor NGS accurately and efficiently detects germline predisposition variants in myeloid malignancies
Abstract Background: Germline predisposition occurs in patients of all ages with myeloid malignancies and is important to identify due to im...
Direct oral anticoagulation management to address primary and secondary adherence in atrial fibrillation
Abstract Use of Direct oral anticoagulants (DOAC) has increased exponentially since their introduction in 2010. Over the years they have bee...
Development of an individualized prognostic model based on gut microbiota–related genes in pediatric ALL: A study from the target cohort
Abstract Background: Emerging evidence suggests that host gut microbiota-related genes (GMRGs) are critically involved in orchestrating immu...
Outcomes of marstacimab treatment in adolescent participants with Hemophilia A or B without inhibitors compared with prior routine prophylaxis: Results from the phase 3 BASIS trial
Abstract Background: BASIS (NCT03938792) is an open-label, phase 3 trial of anti-tissue factor pathway inhibitor (TFPI) antibody marstacimab...
Parkinsonism after treatment with anti-CD19 CAR-T: Case report, institutional data review, and pharmacovigilance analysis of the FDA adverse event reporting system database
Abstract Background: Chimeric antigen receptor T-cell (CAR-T) therapies target cell surface proteins, most notably CD19 and B-cell maturatio...
Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up
Abstract Introduction: The introduction of the Bruton tyrosine kinase inhibitor acalabrutinib combined with bendamustine and rituximab (ABR)...
Clinical outcomes and prognostic factors in AML patients undergoing second allogeneic hematopoietic stem cell transplantation
Abstract Background/Aim A second allogeneic hematopoietic stem cell transplantation (SCT2) offers a potential cure for r...
Novel von willebrand factor targeting thrombolytic TGD001 is effective in diverse thrombotic models, demonstrating its potential as a universal thrombolytic
Abstract Thrombi have heterogeneous compositions, limiting the efficacy of standard-of-care (SoC) thrombolytic treatments. While fibrin has...
Pharmacokinetics and cardiac impact of arsenic trioxide (ATO) oral solution (SDK001) under fasting, fed, and calcium carbonate co-administration conditions compared with intravenous ATO in patients with acute promyelocytic leukemia
Abstract Background Arsenic Trioxide (ATO) is a crucial component of the treatment of Acute Promyelocytic Leukemia (APL), with frontline use...
Clinical spectrum of noonan syndrome–associated myeloproliferative disorder
Abstract Introduction Noonan syndrome (NS) is a genetic disorder characterized by a short stature, facial dysmorphism, and congenital heart...
Efficacy of BV-R2 therapy in relapsed/refractory DLBCL: A single centre preliminary retrospective analysis
Abstract Background: Patients with transplant-ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma (TIE R/R DLBCL) face poor outcome...
Disease monitoring and management among pediatric patients with pyruvate kinase deficiency: Real-world practices from pyruvate kinase deficiency registries prior to 2024 international expert guidelines
Abstract Introduction: Pyruvate kinase (PK) deficiency is a rare, genetic disease that leads to chronic hemolytic anemia and potentially lif...
CCR2 chemokine receptor promotes hematopoietic stem and progenitor cell mobilization
Abstract Hematopoietic stem and progenitor cell (HSPC) transplantation offers a lifesaving therapy for many hematological and non-hematologi...
Polyclonal somatic gene rescue via uniparental disomy confers multilineage hematopoietic potential in treatment-independent patients with DBA syndrome
Abstract Diamond-Blackfan anemia syndrome (DBAS) is an inherited bone marrow failure disorder typically caused by heterozygous mutations in...
Anti-CD7 CAR T-cell therapy for ultra-high-risk relapsed/refractory T-ALL/lbl: Insights into lineage switch and consolidation strategies
Abstract Patients with refractory or relapsed (R/R) T-cell lymphoblastic lymphoma/leukemia (T-LBL/ALL) face dismal prognoses. To address thi...
Overestimation of collection volume with spectra optia: Determining factors and corrective strategies
Abstract BACKGROUND Accurate quantification of hematopoietic stem cells (HSCs) collected during apheresis is essential for informing clinica...
First worldwide real-life data on fixed-duration ibrutinib+venetoclax treatment for previously untreated CLL/SLL patients: Updated interim analysis of Spain´s LI+VE observational study
Abstract Background Ibrutinib plus venetoclax (I+V) is the first once-daily, all-oral, fixed-duration regimen approved by EMA in front line...
Cladribine, cytarabine, and venetoclax-based regimens are associated with durable remissions in patients (pts) with newly diagnosed Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation
Abstract Background: Cladribine-based regimens combined with venetoclax (VEN) have shown promising efficacy in newly diagnosed (ND) acute my...
IL‑10 limits CLL progression by reprogramming T cell exhaustion and myeloid suppression
Abstract Despite major advances in immunotherapy, respective treatments often show only limited benefit in patients with chronic lymphocytic...
Deciphering the role of EP300 in maintaining the enhancer landscape and lineage-specific epigenetic vulnerability in multiple myeloma
Abstract BackgroundGene expression is regulated by post-translational modification of chromatin structures by a network of epigenetic regula...